Precursor Cell Lymphoblastic Leukemia-Lymphoma × Decitabine × Clear all HEM-iSMART A
Phase 1/2 Withdrawn
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase 1/2 Terminated
23 enrolled 13 charts
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Phase 1/2 Completed
65 enrolled 12 charts
Phase I, Dose Escalation Study of Decitabine
Phase 1 Completed
3 enrolled
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Phase 2 Terminated
15 enrolled 8 charts
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)
Phase 1 Completed
40 enrolled
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Completed
80 enrolled
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Phase 1 Completed
36 enrolled
Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1 Terminated
21 enrolled
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases
Phase 1 Completed
50 enrolled
Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
14 enrolled